-
Inhibition of nucleophosmin 1 suppresses colorectal cancer tumor growth of patient -derived xenografts via activation of p53 and inhibition of AKT Cancer Biol. Ther. (IF 3.659) Pub Date : 2021-01-15 Angel C.Y. Yu; Yi-Jye Chern; Peter Zhang; Clarissa C. Pasiliao; Mahbuba Rahman; George Chang; Jianhua Ren; Isabella T. Tai
ABSTRACT The nucleophosmin 1 (NPM1) protein is frequently overexpressed in various cancers compared to normal tissues and represents a potential biomarker for maliganancy. However, its role in colorectal cancer (CRC) is still not fully understood. In this report, we show that NPM1 levels in CRC correlate with prognosis and sensitivity to chemotherapy. NPM1 expression was found to be significantly increased
-
The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-12-30 Zhaoting Meng; Ting Li; Pei Wang; Analyn Lizaso; Dingzhi Huang
ABSTRACT Acquired mutations in anaplastic lymphoma kinase (ALK) gene have been implicated as the major resistance mechanism to ALK inhibitors; however, information on the treatment options after acquiring novel ALK secondary mutations is limited. Herein, we report the efficacy of lorlatinib upon the detection of a novel ALK G1202L after progression on brigatinib. Our patient was a 30-year-old man with
-
HMGA2 promotes breast cancer metastasis by modulating Hippo-YAP signaling pathway Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-12-13 Jianxin Xu; Xuejiao Fang; Luye Long; Sixuan Wang; Shihan Qian; Jianxin Lyu
ABSTRACT Background Breast cancer is the most common cancer in women, and triple-negative breast cancer (TNBC) accounts for about 15–20% of all breast cancer. High mobility group AT-hook 2 (HMGA2) is overexpressed in some tumors and closely associated with patients’ prognosis. However, the mechanisms involved in the regulation of HMGA2 in TNBC still remain unclear. Methods In this study, HMGA2 level
-
Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3 Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-29 Chin-Yu Wang; Bai-Ling Lin; Chung-Hsuan Chen
ABSTRACT We developed a DNA aptamer, Ap52, against the shared tumor-specific MAGE-A3111-125 peptide antigen that was used to target multiple types of cancer cells. Here we report the in vivo study of mice implanted with pancreatic tumor cells AsPC-1, which demonstrates accumulation of phosphorothioate-modified Ap52 (ThioAp52) at the xenograft tumor following either intravenous or in situ injection
-
MAP17 contributes to non-small cell lung cancer progression via suppressing miR-27a-3p expression and p38 signaling pathway Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-12-07 Qian Liang; Huan Zhang
ABSTRACT Problem and aim The overexpression of MAP17 has been reported in various human carcinomas. However, its molecular mechanism in non-small cell lung cancer (NSCLC) has not been fully understood. Our study aimed to reveal the molecular mechanism of NSCLC that involved MAP17 and identify its target miRNA. Methods RT-qPCR and immunoblot assays were conducted to measure the expression of mRNA and
-
CXCL6 regulates cell permeability, proliferation, and apoptosis after ischemia–reperfusion injury by modulating Sirt3 expression via AKT/FOXO3a activation Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-26 Xiaolin Wang; Yuanqiang Dai; Xiaoxiu Zhang; Ke Pan; Yu Deng; Jiafeng Wang; Tao Xu
ABSTRACT Chemokine (C-X-C motif) ligand 6 (CXCL6), a member of the CXC chemokine family, reportedly mediates several processes such as inflammation, immunoreaction, cell growth, and metastasis through interaction with the chemokine receptors CXCR1 and CXCR2 in humans; further, CXCR1 and CXCR2 can promote repair and regeneration of organs or tissues after ischemia–reperfusion injury (IRI). In this study
-
The top 100 most-cited papers in long non-coding RNAs: a bibliometric study Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-12-14 Meng-Si Peng; Chang-Cheng Chen; Juan Wang; Yi-Li Zheng; Jia-Bao Guo; Ge Song; Xue-Qiang Wang
ABSTRACT Up to 90% of the human genome is transcribed into Long-noncoding RNAs (lncRNAs) that longer than 200 nucleotides but do not code for proteins. LncRNAs play a vital role in a broad range of biological process, it’s dysregulations and mutations are linked to the development and progression of various complex human diseases. Given the dramatic changes and growing scientific outputs in lncRNAs
-
Epigenetic modulation of FBW7/Mcl-1 pathway for lung cancer therapy Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-12-18 Mi Jeong Kim; Guo Chen; Gabriel L. Sica; Xingming Deng
ABSTRACT Methylation induces epigenetic silencing of tumor suppressor genes in human lung cancer. Inhibition of DNA methyltransferases by decitabine (DAC) can demethylate and activate epigenetically silenced tumor suppressor genes. Epigenetic therapy using DAC should be an attractive strategy for lung cancer therapy. FBW7 is a tumor suppressor that functions as an Mcl-1 E3 ligase to degrade Mcl-1 by
-
JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-12-27 Govind Babu; Padmaparna Chaudhuri; Manoj Rajappa; Manjusha Biswas; Bipinesh Sansar; Chethan Rajegowda; Aneesha Radhakrishnan; Jayshree Advani; Biplab Tewary; Padhma Radhakrishnan; Saravanan Thiyagarajan; Aditi Chatterjee; Ram Shankar Upadhayaya; Pradip K Majumder
ABSTRACT The prognosis of AML is generally poor, with 5-year survival rate of 25%. There has been substantial progress in identification of new therapeutic targets, along with approval of at least three targeted therapies for AML in recent years. Nevertheless, treatment has largely remained unchanged over couple of decades, with ~40% patients not achieving remission. AML is a highly heterogenous disease
-
The therapeutic potential of attenuated diphtheria toxin delivered by an adenovirus vector with survivin promoter on human lung cancer cells Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-12-30 Lvxia Dai; Xiaoping Yu; Sizhou Huang; Yanjuan Peng; Jianmin Liu; Tian Chen; Xin Wang; Qiaofeng Liu; Yanfeng Zhu; Dengbang Chen; Xiaohua Li; Yu Ou; Yi Zou; Qu Pan; Kang Cao
ABSTRACT Adenoviral vectors are superior to plasmid vectors in their gene transport efficiency. The A subunit of the diphtheria toxin (DTA) gene is a popular suicide gene in cancer gene therapy. However, DTA is seldom used in adenoviral therapy due to its great toxicity. The toxicity of DTA is so great that even a single molecule of DTA is enough to kill one cell. To avoid this highly toxic effect
-
Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease Cancer Biol. Ther. (IF 3.659) Pub Date : 2021-01-11 Rebecca C. Arend; Amy Jackson-Fisher; Ira A. Jacobs; Jeffrey Chou; Bradley J. Monk
ABSTRACT Recently approved therapies have contributed to a significant progress in the management of ovarian cancer; yet, more options are needed to further improve outcomes in patients with advanced disease. Here we review the rationale and ongoing clinical trials of novel combination strategies involving chemotherapy, poly ADP ribose polymerase, programmed death 1 (PD-1)/PD-ligand 1 immune checkpoint
-
MAP17 contributes to non-small cell lung cancer progression via suppressing miR-27a-3p expression and p38 signaling pathway Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-12-07 Qian Liang; Huan Zhang
ABSTRACT Problem and aim The overexpression of MAP17 has been reported in various human carcinomas. However, its molecular mechanism in non-small cell lung cancer (NSCLC) has not been fully understood. Our study aimed to reveal the molecular mechanism of NSCLC that involved MAP17 and identify its target miRNA. Methods RT-qPCR and immunoblot assays were conducted to measure the expression of mRNA and
-
Primary squamous cell carcinoma of the breast: report of two cases with HER2 overexpression Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-12 Ruixue Lei; Lanfang Miao
ABSTRACT Objective To investigate the clinicopathologic features and immunophenotype of primary squamous cell carcinoma of the breast (PSCCB) with HER2 overexpression. Methods Two cases of PSCCB with HER2 overexpression were retrospectively reviewed, and the pathological features, immunophenotype and prognosis were discussed. Results The tumor showed malignant squamous cells arranged in sheets, groups
-
Heparan sulfate proteoglycans as targets for cancer therapy: a review Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-12 Jessica Oyie Sousa Onyeisi; Bianca Zaia Franco Ferreira; Helena Bonciani Nader; Carla Cristina Lopes
ABSTRACT Heparan sulfate proteoglycans (HSPGs) play important roles in cancer initiation and progression, by interacting with the signaling pathways that affect proliferation, adhesion, invasion and angiogenesis. These roles suggest the possibility of various strategies of regulation of these molecules. In this review, we demonstrated that the anticancer drugs can regulate the heparan sulfate proteoglycans
-
Maintenance avelumab for metastatic urothelial cancer: a new standard of care Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-18 Alisa Erck; Jeanny B. Aragon-Ching
ABSTRACT The Javelin Bladder 100 trial was the first trial to establish the role of switch maintenance therapy in patients with metastatic urothelial cancer using avelumab, a PD-L1 inhibitor, for patients who achieve complete response, partial response, or stable disease to standard chemotherapy of 4–6 cycles with gemcitabine and cisplatin or carboplatin. Improvement in parameters of overall survival
-
Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-05 Dantong Sun; Dong Liu; Qiaoling Liu; Helei Hou
ABSTRACT Immune checkpoint inhibitors have demonstrated promising efficacy and tolerable safety for advanced malignancies. However, a proportion of patients who had received immunotherapy may experience hyperprogressive disease and a resultant poor prognosis. Here, we report a patient with advanced esophageal squamous carcinoma who developed hyperprogressive disease shortly after immunotherapy. This
-
Fruquintinib effectively controlled the advanced small bowel adenocarcinoma progressed after multiple lines of palliative treatment: a case report and literature review Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-05 Yuwei Ding; Juan Wang; Ning Zhu; Dong Xu; Kefeng Ding; Ying Yuan
ABSTRACT Small bowel cancer is a very rare disease. It can be treated by surgery at early stages; however, there is no standard therapeutic strategy established for the treatment of unresectable and/or metastatic diseases. Here we present a case of metastatic small bowel adenocarcinoma, which progressed after sequential treatment with XELOX (capecitabine and oxaliplatin), FOLFIRI (fluorouracil, leucovorin
-
Interplay between aging, lung inflammation/remodeling, and fibronectin EDA in lung cancer progression Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-23 John C. Greenwell; Edilson Torres-Gonzalez; Jeffrey D. Ritzenthaler; Jesse Roman
ABSTRACT Lung cancer remains the leading cause of cancer death in the United States. Since most lung cancers occur in aged individuals with chronic lung disorders characterized by inflammation and/or fibrosis, we hypothesized that aging and tissue inflammation/remodeling act in concert to promote lung cancer progression. To test this, we engaged in studies using young and aged C57BL/6 mice in conjunction
-
A novel prognostic biomarker for muscle invasive bladder urothelial carcinoma based on 11 DNA methylation signature Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-05 Yueyi Feng; Yiqing Jiang; Qingting Feng; Lingkai Xu; Yun Jiang; Fang Meng; Xiaochen Shu
ABSTRACT Muscle-invasive bladder urothelial carcinoma (MIBC) is a highly invasive cancer, which leads to prevalent recurrence and poor prognosis. Exploring the association of DNA methylation and the prognosis of MIBC will thus be of important value in clinical management and treatment. Bumphunter method and adaptive lasso regression were used to explore the relationship between different methylation
-
The therapeutic potential of exosomal miR-22 for cervical cancer radiotherapy Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-16 Hiromi Konishi; Masami Hayashi; Kohei Taniguchi; Mayumi Nakamura; Yuki Kuranaga; Yuko Ito; Yoichi Kondo; Hiroshi Sasaki; Yoshito Terai; Yukihiro Akao; Masahide Ohmichi
ABSTRACT Cervical cancer is the fourth-most prevalent malignancy in women. For advanced cervical cancer, radiotherapy is a major treatment. Micro RNAs (miRNAs) are small, noncoding RNAs that negatively regulate the target gene expression posttranscriptionally. miR-22 is frequently downregulated in various cancers including cervical cancer, and is associated with a poor prognosis in cervical cancer
-
The oncogenic role of SOX8 in endometrial carcinoma Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-16 Wenyan Tian; Zhanghuan Li; Lu Bai; Lingli Chen; Ye Yan; Huihui Li; Yanyan Han; Fei Teng; Chao Gao; Fengxia Xue; Yingmei Wang
ABSTRACT Endometrial carcinoma (EC) remains one of the most prevalent forms of cancer to impact the female reproductive system, yet the mechanisms governing its development and progression are incompletely understood. We, therefore, sought to assess the relevance of SOX8 to EC progression and patient prognosis. Array comparative genomic hybridization (aCGH) was performed using samples from 50 patients
-
CYP2C8 regulated by GAS5/miR-382-3p exerts anti-cancerous properties in liver cancer Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-12 Kezhi Li; Yonglun Chen
ABSTRACT A cornucopia of literatures has characterized the involvement of a host of functional molecules in liver cancer. Herein, according to online datasets, we found that cytochrome P450 family 2 subfamily C member 8 (CYP2C8) was downregulated in liver cancer, and high CYP2C8 expression was associated with favorable overall survival. Lower levels of CYP2C8 were confirmed in liver cancer cells. CYP2C8
-
Desmoglein-2 as a prognostic and biomarker in ovarian cancer Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-20 Jiho Kim; Peter Beidler; Hongjie Wang; Chang Li; Abdullah Quassab; Cari Coles; Charles Drescher; Darrick Carter; André Lieber
ABSTRACT Greater than 80% of all cancer cases are carcinomas, formed by the malignant transformation of epithelial cells. One of the key features of epithelial tumors is the presence of intercellular junctions, which link cells to one another and act as barriers to the penetration of molecules. This study assessed the expression of desmoglein-2, an epithelial junction protein, as a prognostic and diagnostic
-
miR-219a-1 inhibits colon cancer cells proliferation and invasion by targeting MEMO1 Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-20 Keqing Xu; Jie Shi; Dongping Mo; Yanhua Yang; Qiang Fu; Ying Luo
ABSTRACT Colon cancer is the third most common cancer worldwide. Many miRNAs have been reported to be involved in colon cancer progression. However, there are only a few studies on the role of miR-219a-1 in colon cancer, and the molecular mechanisms involved remain unclear. The aim of this study was to investigate the miR-219a-1 level in patients with colon cancer and to explore both the effects and
-
rAAV9-UPII-TK-EGFP can precisely transduce a suicide gene and inhibit the growth of bladder tumors Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-20 Foyan Lian; Qiang Ye; Bing Feng; Hui Cheng; Shaomin Niu; Ning Fan; Degui Wang; Zhiping Wang
ABSTRACT Bladder cancer is a common and widespread cancer of the human urinary system, and its incidence is increasing. Gene therapy is a promising treatment of bladder cancer. In our study, a recombinant adeno-associated virus (rAAV9-UPII-TK-EGFP) driven by a UPII promoter was constructed. The efficacy and safety of infection of bladder cells was tested in vivo and in vitro. The ability of rAAV9-UPII-TK-EGFP
-
Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-20 Ying Wang; Xin Zhang; Xin Xie; Wei Chen; Min Li; Dongmei Diao; Chengxue Dang
ABSTRACT Breast cancer is the most common malignant tumor in women. Its incidence is associated with obesity and metabolic syndrome (MetS), which are highly prevalent world widely and have been identified as poorer prognosis factors in breast cancer including triple-negative breast cancer (TNBC), which has poorer response to chemotherapy, radiotherapy, and endocrine therapy. Programmed death ligand
-
Correction Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-09
(2020). Correction. Cancer Biology & Therapy: Vol. 21, No. 12, pp. 1191-1192.
-
Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-23 Lei Liu; Yuanyuan Liu; Longbo Gong; Miao Zhang; Wenbin Wu
ABSTRACT The current evidence regarding immunotherapy plus targeted therapy in esophageal neuroendocrine carcinoma (NEC) is lacking. Camrelizumab is a programmed cell death protein 1 inhibitor. Apatinib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. A 50-year-old female was initially diagnosed as primary esophageal NEC. Neoadjuvant chemotherapy and Ivor Lewis
-
Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-29 Liang Xuan; Bing Sun; Xiangying Meng; Chao Liu; Yang Cong; Shikai Wu
ABSTRACT Docetaxel is an important anti-microtubule agent used to treat a variety of solid tumors, including breast cancer; notably, docetaxel-containing regimens improve outcomes for patients in metastatic, adjuvant, and neoadjuvant settings. However, the effectiveness of docetaxel in clinical practice can be compromised by suboptimal management of side effects. Here, we report two cases of docetaxel-based
-
Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-14 Joseph T. Decker; Pridvi Kandagatla; Lei Wan; Regan Bernstein; Jeffrey A. Ma; Lonnie D. Shea; Jacqueline S. Jeruss
ABSTRACT The efficacy of trastuzumab, a treatment for HER2+ breast cancer, can be limited by the development of resistance. Cyclin E (CCNE) overexpression has been implicated in trastuzumab resistance. We sought to uncover a potential mechanism for this trastuzumab resistance and focused on a model of CCNE overexpressing HER2+ breast cancer and noncanonical phosphorylation of the TGF-β signaling protein
-
Metallophosphoesterase 1, a novel candidate gene in hepatocellular carcinoma malignancy and recurrence Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-15 Xinguo Chen; Jing Xu; Peixiao Wang; Lei Shang; Jing Guo; Lihong Huang; Yide A. Jiang; Jinhong Chen; Huijuan Chen; Yukui Shang; Qing Zhang
ABSTRACT Background There is an unmet need to identify novel mechanism-based prognostic genes associated with hepatocellular carcinoma (HCC) recurrence that can predict patient outcomes and provide therapeutic targets. This study aims to identify potential novel driver genes and mutations in HCC. Methods Single nucleotide variations (SNVs) contributing to HCC recurrence were identified using whole-exome
-
FGF13 interaction with SHCBP1 activates AKT-GSK3α/β signaling and promotes the proliferation of A549 cells Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-16 Hongzhao Lu; Meichen Yin; Ling Wang; Jia Cheng; Wei Cheng; Huanping An; Tao Zhang
ABSTRACT FGF13, a member of the FGF subfamily, has been found to be highly expressed in cancer cells such as prostate cancer, melanoma, glioma and multiple myeloma. However, the mechanism of FGF13 function during cancer cell proliferation remains to be unexplored, especially Non-small cell lung cancer (NSCLC). In this study, the cell proliferation effect of FGF13 on A549 cells was checked by CCK-8
-
Long non-coding RNA FALEC promotes colorectal cancer progression via regulating miR-2116-3p-targeted PIWIL1 Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-19 Huiyuan Jiang; Haiyi Liu; Bo Jiang
(2020). Long non-coding RNA FALEC promotes colorectal cancer progression via regulating miR-2116-3p-targeted PIWIL1. Cancer Biology & Therapy: Vol. 21, No. 11, pp. 1025-1032.
-
Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-12 Ricardo E Perez; Sarah Calhoun; Daeun Shim; Victor V. Levenson; Lei Duan; Carl G. Maki
ABSTRACT Prolyl endopeptidase (PREP), also known as prolyl oligopeptidase (POP), is an enzyme that cleaves short peptides (<30 amino acids in length) on the C-terminal side of proline. PREP is highly expressed in multiple carcinomas and is a potential target for cancer therapy. A potent inhibitor of PREP, Y-29794, causes long-lasting inhibition of PREP in mouse tissues. However, there are no reports
-
Tumor-associated macrophages promote human hepatoma Huh-7 cell migration and invasion through the Gli2/IGF-II/ERK1/2 axis by secreting TGF-β1 Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-21 Mei Liu; Yuan-Bin Zhong; Jia Shao; Cheng Zhang; Chao Shi
ABSTRACT Aim In this study, we explored the ability of TAMs to affect the malignant phenotype of human hepatoma Huh-7 cells through the Gli2/IGF-II/ERK1/2 pathway. Methods The TAMs were characterized by flow cytometry and ELISA assays. Huh-7 cells were treated with conditioned medium of TAMs (TAMs-CM), and the proliferation, migration and invasion abilities were measured by CCK-8, Transwell and scratch
-
LRRC75A-AS1 targets miR-199b-5p/PDCD4 axis to repress multiple myeloma Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-01 Quantang Pang; Yanyan Wang; Dapeng Bi; Hongyu Lu
ABSTRACT Background Multiple functions of miR-199b-5p in diseases have been demonstrated by existing studies. However, never has the correlation between miR-199b-5p and multiple myeloma (MM) been established. Methods qRT-PCR analyzed RNA expression and western blot measured protein expression. Cell proliferation ability was tested via colony formation and EdU assays, and apoptosis was determined via
-
Rituximab-induced acute thrombocytopenia in patients with splenomegaly B Cell lymphoma: an underdiagnosed but severe complication Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-29 Yujie Jiang; Jiqing Song; Na Wang; Dai Yuan; Lili Feng; Huiting Qu; Juan Fan
ABSTRACT Rituximab is popularly used in the treatment of B-cell lymphomas that bear CD20 antigen. Most of the adverse events (AEs) induced by rituximab are infusion-related symptoms. However, rituximab-induced acute thrombocytopenia (RIAT), which often develops within the 1–3 days after rituximab administration, is relatively unusual, severe, and usually self-recovering. Until now, most of the reports
-
Standardized uptake value (SUVmax) in 18F-FDG PET/CT is correlated with the total number of main oncogenic anomalies in cancer patients Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-01 Amin Haghighat Jahromi; Geraldine Chang; Razelle Kurzrock; Carl K. Hoh
ABSTRACT Cancer diagnosis and therapy is quickly moving from the traditional histology-based approaches to genomic stratification, providing a huge opportunity for radiogenomics, associating imaging features with genomic data. Genome sequencing is time consuming, expensive and invasive whereas 18F-FDG PET/CT is readily available, fast and noninvasive. The aim of this study was to determine the relationship
-
LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-11-03 Weiping Leng; Qingzuo Liu; Shidong Zhang; Dekang Sun; Yongshun Guo
ABSTRACT LncRNA AFAP1-AS1 has been corroborated to function in diverse cancers. Our aim was to investigate the molecular mechanism of AFAP1-AS1 in PTX resistance in PCa. The levels of AFAP1-AS1, miR-195-5p, and FKBP1A were checked by qRT-PCR. 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) assay was employed to assess the resistance of PTX-resistant PCa cells to PTX. Flow cytometry
-
The use of hedgehog antagonists in cancer therapy: a comparison of clinical outcomes and gene expression analyses. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-09-11 Burthia E Booker,Adam D Steg,Stefan Kovac,Charles N Landen,Hope M Amm
ABSTRACT Hedgehog (HH) signaling, a critical developmental pathway, has been implicated in cancer initiation and progression. With vismodegib and sonidegib having been approved for clinical use, increasing numbers of HH inhibitors alone and in combination with chemotherapies are in clinical trials. Here we highlight the clinical research on HH antagonists and the genetics of response to these compounds
-
Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-08-26 Vincent Chau,Ravi A Madan,William D Figg
ABSTRACT The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free survival (PFS), objective response rate (ORR), and time to pain progression in patients who harbor
-
Rac1 repression reverses chemoresistance by targeting tumor metabolism. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-08-31 Shanmugasundaram Ganapathy-Kanniappan
ABSTRACT Tumor metabolism is exemplified by the increased rate of glucose utilization, a biochemical signature of cancer cells. The enhanced glucose hydrolysis enabled by the augmentation of glycolytic flux and the pentose phosphate pathway (PPP) plays a pivotal role in the growth and survival of neoplastic cells. In a recent report, it has been shown that in human breast cancer the GTP binding protein
-
Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-07 Timothy Price; Agnes Ang; Michael Boedigheimer; Tae Won Kim; Jin Li; Stefano Cascinu; Paul Ruff; Attili Satya Suresh; Anne Thomas; Sergei Tjulandin; Marc Peeters
ABSTRACT Background Antibodies against epidermal growth factor receptor (EGFR), panitumumab, a fully human monoclonal antibody, and cetuximab, a human/mouse chimeric monoclonal antibody, have shown clinical efficacy in metastatic colorectal cancer (mCRC). In the phase 3 noninferiority ASPECCT (ClinicalTrials.gov, NCT01001377) study, panitumumab was demonstrated to be noninferior to cetuximab and provided
-
Epigenetic age acceleration of early stage hepatocellular carcinoma tightly associated with hepatitis B virus load, immunoactivation, and improved survival. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-09-11 Xiaole Fan,Hongxin Yuan,Suming Zhao,Xiaohu Yang,Rongfeng Shi,Jingli Wang,Hui Zhao
ABSTRACT Properly stratifying high-risk individuals with early stage hepatocellular carcinoma (HCC) is essential to identify patients in which the potentially therapies can be offered. To this context, we systematically investigated the prognostic value of epigenetic clock with early stage HCC as well as the association with other molecular characteristics. We computed DNA methylation (DNAm) age of
-
Long non-coding RNA ARAP1-AS1 promotes the proliferation and migration in cervical cancer through epigenetic regulation of DUSP5 Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-09-28 Han Min; Wenjing He
ABSTRACT Emerging reports have indicated that long non-coding RNAs (lncRNAs) play pivotal roles in multiple cancers, containing cervical cancer. LncRNA ARAP1 antisense RNA 1 (ARAP1-AS1) was previously identified as a tumor-promoter in bladder cancer. However, the expression profile and possible modulation mechanism of ARAP1-AS1 in cervical cancer need to be further studied. In the current research
-
miR-221-3p promotes hepatocellular carcinogenesis by downregulating O6-methylguanine-DNA methyltransferase Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-06 Zushun Chen; Bangde Xiang; Lunan Qi; Shaoliang Zhu; Lequn Li
ABSTRACT This study aimed to investigate the influence of miR-221-3p and O6-methylguanine-DNA methyltransferase (MGMT) interaction in human hepatocellular carcinoma (HCC), thereby revealing a novel molecular mechanism of hepatic carcinogenesis involving miR-221-3p and MGMT. Fluorescence qPCR and immunoblot assays were performed to determine the expression of RNA and protein in HCC tissues and cell
-
LncRNA WWOX-AS1 sponges miR-20b-5p in hepatocellular carcinoma and represses its progression by upregulating WWOX. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-09-15 Dafeng Xu,Xiangmei Liu,Jincai Wu,Yu Wang,Kailun Zhou,Wenmei Chen,Jiacheng Chen,Cheng Chen,Liang Chen
ABSTRACT Increasing evidence has revealed that long noncoding RNAs (lncRNAs) emerge as pivotal regulators in diverse cancers, including hepatocellular carcinoma (HCC). This study was conducted to investigate the role of lncRNA WWOX antisense RNA 1 (WWOX-AS1) in HCC progression. Our present study illustrated that WWOX-AS1 was lowly expressed in HCC tissues and cell lines. High WWOX-AS1 expression was
-
Tumor associated neutrophils promote the metastasis of pancreatic ductal adenocarcinoma. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-08-23 Tao Lianyuan,Li Gang,Tao Ming,Xiu Dianrong,Yuan Chunhui,Ma Zhaolai,Jiang Bin
ABSTRACT The aim of this study was to investigate the role of tumor-associated neutrophils (TANs) in the metastasis of pancreatic ductal adenocarcinoma (PDAC), to explore the regulation of TANs, and to determine the mechanisms governing the metastasis of PDAC. The correlation between neutrophils and the patient’s clinical pathological data was first evaluated. Then, the effects of neutrophils on the
-
Successful gene therapy requires targeting the vast majority of cancer cells Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-09-30 Takuya Sagara; Marija Debeljak; Chapman M. Wright; Nicole M. Anders; Hong Liang; Michelle A. Rudek; Marc Ostermeier; James R. Eshleman; Yoshihisa Matsushita
ABSTRACT Suicide gene therapy using gene-directed enzyme prodrug therapy (GDEPT) is based on delivering a gene-encoded enzyme to cells that converts a nontoxic prodrug into its toxic metabolite. The bystander effect is thought to compensate for inefficiencies in delivery and expression because the produced toxic metabolite can spread to adjacent non-expressing cells. The purpose of this study was to
-
Overexpression of family with sequence similarity 134, member B (FAM134B) in colon cancers and its tumor suppressive properties in vitro. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-08-28 Katherine Ting-Wei Lee,Farhadul Islam,Jelena Vider,Jeremy Martin,Anna Chruścik,Cu-Tai Lu,Vinod Gopalan,Alfred Kin-Yan Lam
ABSTRACT This study aims to investigate the overexpression-induced properties of tumor suppressor FAM134B (family with sequence similarity 134, member B) in colon cancer, examine the potential gene regulators of FAM134B expression and its impact on mitochondrial function. FAM134B was overexpressed in colon cancer and non-neoplastic colonic epithelial cells. Various cell-based assays including apoptosis
-
Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-12 Fangran Liu; Jiao Liu; Jinguo Zhang; Jimin Shi; Lu Gui; Guoxiong Xu
ABSTRACT Signal transducer and activator of transcription 1 (STAT1) is related to the immune microenvironment of tumorigenesis. The programmed cell death 1 (PD-1) and its ligand (PD-L1) have been reported to be important in immunotherapy by mediating tumor immune evasion. Blocking the PD-1/PD-L1 pathway can restore the endogenous anti-tumor immune response. This study aimed to examine the expression
-
Circular RNA hsa_circ_0003204 promotes cervical cancer cell proliferation, migration, and invasion by regulating MAPK pathway Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-10-13 Xiao-Bin Huang; Kai-Jing Song; Guo-Bin Chen; Rui Liu; Zhuo-Fei Jiang; Yuan-Li He
ABSTRACT Cervical cancer (CC) is the second most common malignancy in women worldwide. The mechanism underlying CC development remains unclear. Recently, Circular RNAs (circRNAs)have attracted attention because of its role in tumorigenesis. To investigate circRNAsin CC, RNA sequencing was employed to characterize circRNA expression profile between CC tissues and matched adjacent normal tissues. The
-
Long non-coding RNA (lncRNA) and epithelial-mesenchymal transition (EMT) in colorectal cancer: a systematic review. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-07-30 Stephen J O'Brien,Campbell Bishop,Jacob Hallion,Casey Fiechter,Katharina Scheurlen,Mason Paas,James Burton,Susan Galandiuk
Background Colorectal cancer (CRC) is a leading cause of cancer-related death. Epithelial-mesenchymal transition (EMT) is a major process in tumor metastasis development. This systematic review aims to describe the role of long non-coding RNA (lncRNA) in EMT in CRC. Methods The electronic databases, PubMed, Cochrane, and EMBASE, were searched from January1990 to June 2019 to identify studies examining
-
Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-08-13 Whitney F Handy,Keith T Schmidt,Douglas K Price,William D Figg
The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were genotyped in a recent study to detect HSD3B1 variance and to determine 2-y freedom from castration-resistant
-
Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-06-28 Amanda M Pattison,Joshua R Barton,Ariana A Entezari,Alicja Zalewski,Jeff A Rappaport,Adam E Snook,Scott A Waldman
Most sporadic colorectal cancer reflects acquired mutations in the adenomatous polyposis coli (APC) tumor suppressor gene, while germline heterozygosity for mutant APC produces the autosomal dominant disorder Familial Adenomatous Polyposis (FAP) with a predisposition to colorectal cancer. In these syndromes, loss of heterozygosity (LOH) silences the remaining normal allele of APC, through an unknown
-
Long non-coding RNA SLCO4A1-AS1 drives the progression of non-small-cell lung cancer by modulating miR-223-3p/IKKα/NF-κB signaling. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-07-20 Qingpeng Li,Bo Jiang,Yang Qi,Hu Zhang,Haitao Ma
Globally, lung cancer is known as a major cause of cancer-associated death and non-small-cell lung cancer (NSCLC) accounts for majority of all cases. Growing evidence has emerged that long non-coding RNAs (lncRNAs) act as vital regulatory molecules in various malignancies. Nevertheless, the function of SLCO4A1 antisense RNA 1(SLCO4A1-AS1) in NSCLC is vague. This study intended to investigate the biological
-
FERMT1 promotes gastric cancer progression by activating the NF-κB pathway and predicts poor prognosis. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-07-29 Hua Fan,Shengjun Zhang,Yu Zhang,Wu Liang,Bo Cao
Recent studies have reported that FERMT1, a newly discovered adhesion protein, contributes to an aggressive phenotype in several solid malignancies. However, the function and regulatory mechanism of FERMT1 in gastric cancer remain unknown. We found that FERMT1 was overexpressed in gastric cancer tissues compared with normal tissues. Clinical data analysis indicated that the expression of FERMT1 correlated
-
High TKTL1 expression as a sign of poor prognosis in colorectal cancer with synchronous rather than metachronous liver metastases. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-08-14 Reetta Peltonen,Kaisa Ahopelto,Jaana Hagström,Camilla Böckelman,Caj Haglund,Helena Isoniemi
Colorectal cancer (CRC) is the third most common cancer in the world. More than half of all affected patients develop liver metastases during the course of the disease, and over half experience recurrence despite radical primary surgery. Transketolase-like protein 1 (TKTL1) is a key enzyme in the glucose metabolism of cancer cells, and its expression in tumor tissue was previously shown to indicate
-
Radiotherapy for patients with stage IV classical Hodgkin lymphoma: a propensity-matched analysis of the surveillance, epidemiology, and end results database. Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-08-23 Shijie Wang,Mingfang Jia,Jianglong Han,Rui Zhang,Kejie Huang,Ping Li,Qin Li,Yunfeng Qiao,Qibin Song,Zhenming Fu
Background The survival advantage of radiotherapy for patients with stage IV classic Hodgkin lymphoma (HL) has not been adequately evaluated. Methods We analyzed patients with stage IV HL enrolled from the Surveillance, Epidemiology, and End Results (SEER) registry from January 2000 to December 2012. Propensity score (PS) analysis with 1:2 matching was performed to ensure well-balanced characteristics
-
Analysis of selective target engagement by small-molecule sphingosine kinase inhibitors using the Cellular Thermal Shift Assay (CETSA). Cancer Biol. Ther. (IF 3.659) Pub Date : 2020-08-23 Jeremy A Hengst,Taryn E Dick,Charles D Smith,Jong K Yun
The recently renewed interest in scientific rigor and reproducibility is of critical importance for both scientists developing new targeted small-molecule inhibitors and those employing these molecule in cellular studies, alike. While off-target effects are common